CytRx (CYTR) Prices 8M Offering; Sees Gross Proceeds of $20M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
CytRx (CYTR) Underwriters Exercise Full 1.2M Common Overallotment
October 19, 2012 12:18 PM EDTCytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, announced today the sale of an additional 1,200,000 shares of common stock pursuant to the exercise in full by the underwriters of the over-allotment option granted to the underwriters in connection with CytRx's recently... More
CytRx (CYTR) Commences Common Offering
October 17, 2012 4:20 PM EDTCytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, announced today its intention, subject to market and other conditions, to commence a public offering of its common stock. CytRx intends to use the net proceeds from the offering to fund... More
